Updated July 9, 2021
See our responses to frequently asked questions related to COVID-19 below. If you don’t find the answer to your question here, please contact one of our support resources.
If you have questions regarding your Genentech medicine please contact the Genentech Patient Resource Center at 1 (877) GENENTECH (436-3683).
We understand that many of our patients and their families are facing personal and financial challenges due to the COVID-19 pandemic. Getting your prescribed medicines should not be one of them.
If you need help paying for your Genentech medicine or if your insurance or financial situation has changed due to the impact of COVID-19, we have existing support programs in place to help patients get the medicines they need. For example:
We are continuing to evolve our services to provide greater flexibility and enable continuity of care.
To learn more, please contact the Genentech Patient Resource Center at 1 (877) GENENTECH (436-3683) or visit this page to learn about our services.
Treatment decisions should be made between a patient and their healthcare provider based on a benefit/risk assessment specific to the individual patient. If you are currently receiving or starting treatment with a Genentech medicine, you should talk with your healthcare provider to determine if receiving a COVID-19 vaccine is right for you and when you should receive it.
We understand how difficult it may be to make treatment decisions at this time when there is limited information available on the safety and efficacy of COVID-19 vaccines in patients receiving a Genentech medicine. Patient safety is Genentech’s highest priority and we are closely monitoring the evolving situation to best understand how COVID-19 vaccines could impact patients treated with our therapies.
For additional medical questions related to your prescribed Genentech medicine, please contact Genentech Medicine Information at 1 (800) 821-8590 or visit https://www.gene.com/contact-us/submit-medical-inquiry.
Genentech currently does not make vaccines, however, we are contributing in the fight against COVID-19 in other ways: our scientific knowledge and research expertise in infectious diseases and in antibody-based therapeutics as well as our skilled workforce and specialized manufacturing capabilities.
As the global COVID-19 situation continues to evolve, we remain focused on ensuring patient safety and data integrity across all of our clinical trials.
The pandemic is now impacting our studies in nearly all regions of the world and we’re working closely with trial sites to find new and flexible ways to adapt to the challenges they are facing and safely enable continued study participation wherever possible.
Each country is in a different phase of COVID-19 outbreak and response, and we support our clinical trial sites in making decisions that are in the best interests of their patients, their institutions, and their communities.
We will continue to assess the situation on an ongoing basis at the study, site and country level.
On June 24, 2021, Genentech announced that the U.S. FDA has issued an Emergency Use Authorization (EUA) for intravenous Actemra® (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Actemra is not FDA-approved for this use. The EUA for Actemra is in effect for the duration of the COVID-19 declaration justifying emergency use of this product, unless terminated or revoked (after which the products may no longer be used under the EUA). View the Genentech press release here.
The FDA Letter of Authorization and Fact Sheets for patients and health care professionals are available for download with the latest information on this EUA. Additional information for health care professionals can be found here: https://www.actemrahcp.com/covid-19.html.
In August 2020, Roche and Genentech announced a collaboration with Regeneron in the fight against COVID-19 to develop, manufacture and distribute Regeneron investigational COVID-19 antibody cocktail of casirivimab and imdevimab to people around the globe. In November 2020, Regeneron announced that REGN-COV™ was granted Emergency Use Authorization in the United States by Food and Drug Administration for the treatment of mild-to-moderate COVID-19 in adults, as well as in paediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization. Additionally, Roche is collaborating with Regeneron to increase global supply of casirivimab and imdevimab. Learn more here and here.
In October 2020, Roche announced a collaboration with Atea Pharmaceuticals on the development, manufacturing, and distribution of AT-527, an orally administered direct-acting antiviral (DAA). Interim results from a Phase II clinical trial for hospitalized patients with mild-to-moderate COVID-19 were announced on June 30, 2021. Phase II (MOONSONG) and Phase III (MORNINGSKY) clinical trials are ongoing outside of the hospital setting for patients with mild or moderate COVID-19. We also expect to start a trial later this year exploring the prevention of COVID-19 in people who may have been exposed to the SARS-CoV-2 virus.
If you are a healthcare provider and have questions about this clinical trial, please contact our clinical trial number at 888-662-6728.
The COVID-19 pandemic continues to evolve, Roche is working closely with governments and health authorities around the world to help ensure that reliable, high-quality diagnostic solutions are available globally. Since March of 2020, Roche has been granted Emergency Use Authorization in the United States by the Food and Drug Administration for a portfolio of lab and point-of-care tests to detect the virus' genetic signature or antibodies to identify an immune response, including:
Please note that these tests must be ordered by a medical professional and people should speak with their healthcare provider about diagnostic testing. For questions, please contact the Roche Diagnostics COVID-19 hotline at 866-987-6243 or visit this page.
The dramatic emergence of the COVID-19 Delta variant as well as the unexpected slowing of vaccination rates in the U.S., has led to an overwhelmingly high incidence of COVID-19 hospitalizations in certain areas of the country. This new wave of the pandemic has led to Genentech experiencing an unprecedented demand for Actemra IV - well-over 400% of pre-COVID-19 levels and it continues to increase.
Genentech is committed to providing Actemra IV to patients in most critical need and our teams have been working as urgently as possible to fulfill the large volume of orders. We’ve recently taken several actions, including allocating all Actemra IV formulations (80, 200 and 400mg vials), drop-shipping medicine direct to hospitals and clinics in COVID-19 hotspots, and collaborating with distributors and shipping carriers to find logistics solutions. You can view our Actemra media statement here.
We have not experienced supply issues for any other medicines in our portfolio related to the global COVID-19 pandemic. We are closely monitoring and responding to the evolving situation and have robust business continuity and mitigation strategies in place. We're working closely with health authorities; federal, state and local governments; and distribution partners to manage inventory levels equitably and best meet the needs of patients.
For customers with further questions, please contact Genentech Customer Service at 1-800-551-2231 or your Account Manager.
All of our manufacturing facilities comply with current Good Manufacturing Practice regulations, which include hygiene standards to safeguard against potential contamination or cross-contamination and mandatory requirements to report any issues.
In addition, we have robust pandemic protocols in place, we are monitoring the situation closely in real-time across our global manufacturing network, and we are confident that we are taking all appropriate steps to minimize infection risks.
Genentech takes the health and safety of our employees, their families and our local communities very seriously, and we are actively responding to the COVID-19 public health issue.
We have a COVID-19 Task Force dedicated to preparing for and protecting against the transmission of COVID-19 on our campuses and in the local community, while ensuring the critical work required to bring our medicines to those who need them continues. The measures we have in place include:
We are aware of individuals who have been on our campuses and subsequently tested positive for COVID-19. Per our protocol, anyone on our campuses identified to have had close contact with diagnosed individuals are notified and advised to take appropriate measures, such as quarantine and/or testing.
We are confident that appropriate measures have and are being taken to support the persons affected and to minimize the risk to others.
Genentech is requiring COVID-19 vaccination for our workforce with limited exceptions, including for medical and religious reasons.
Our decision is grounded in science and driven by the imperative to protect our people and sustain our research, development and manufacturing of essential medicines for patients facing serious and life-threatening diseases, including COVID-19. We believe we must do everything we can to guard against the spread of the virus at our sites. This is in the best public health interest of everyone on our campuses, the communities in which we live and work, and the patients we serve.
In 2020, Genentech and the Genentech Foundation committed $42 million to help address the devastating impact of the COVID-19 pandemic. This support included emergency response grants as well as funds for longer-term recovery efforts, with an emphasis on low-income households and communities of color. Learn more about our approach to giving to help address critical health needs, strengthen schools and provide community grassroots support.
As part of this $42 million commitment, the Genentech Foundation awarded more than $4.3 million to community colleges and universities to address the needs of low-income and BIPOC students, and help prevent deeper learning gaps for this already vulnerable student population.
In addition, Genentech and The Genentech Foundation funded a $3.2 million initiative with the Hasso Plattner Institute of Design (the d. School) at Stanford University to encourage and support bold thinking and new solutions for K-12 learning challenges. The Reach for the Upside initiative invites public school districts and their community partners to workshop and implement tangible solutions to address challenges exacerbated by the COVID-19 pandemic.
Our employees also gave generously through a number of enhanced matching initiatives, including campaigns focused on racial justice and health equity. Over the course of 2020, Genentech employees donated more than $4.8 million to more than 1,500 nonprofit organizations nationwide, much of which was focused on COVID-19 needs.
We recognize that the pandemic is ongoing, and even as we hope for recovery amidst vaccine availability in 2021, the impacts will be long lasting for communities, students and health systems. This is not a one-and-done challenge, and we have embedded awareness of COVID-related challenges and needs into all of our grantmaking. We will continue to learn from our conversations with grantees and stakeholders and seek new ways of driving both immediate relief and longer term transformational change with all of our funding choices.
Please visit funding.gene.com for questions about new or existing grants.